



Invitation to the 2026 Annual General Meeting of Biotest GmbH & Co. KGaA, Dreieich

– ISIN DE000A41YE56 , DE000A41YE49 –
– WKN A41YE5 , A41YE4 –

Unique event identifier: ff022499f133f111b555a908fab7f008

We hereby invite our limited shareholders to the

Annual General Meeting

to be held in person on Tuesday, 21 July 2026, at 10:30 am (CEST), at the business premises of Biotest GmbH & Co. KGaA, Daimlerstraße 1 K, 63303 Dreieich, Germany (the “**Company**”).

I. AGENDA

- 1. Presentation of the adopted annual financial statements of Biotest AG and the approved consolidated financial statements as of 31 December 2025, the management report for Biotest AG and the group, and the report of the Supervisory Board for the financial year 2025**

The aforementioned documents are available on the internet at www.biotest.com from the date of convening the Annual General Meeting, and will be made available for inspection and explained in more detail at the Annual General Meeting.

Prior to the effectiveness of the change of the Company’s legal form from its former legal form as a stock corporation (AG) to its current legal form as a partnership limited by shares (KGaA), the Supervisory Board reviewed and approved the annual financial statements as of 31 December 2025 and the consolidated financial statements as of 31 December 2025 prepared by the Management Board of Biotest AG in accordance with Section 171 of the German Stock Corporation Act (AktG); the annual financial statements are thus adopted.

The annual financial statements are not being adopted by the Annual General Meeting in accordance with Section 286 para. 1 AktG, as the change of legal form of Biotest AG to Biotest GmbH & Co. KGaA took effect only after the Supervisory Board had adopted the annual financial statements, upon registration of the change of legal form in the commercial register on 15 April 2026. Therefore, the Annual General Meeting is not required to pass a resolution on this agenda item 1.

- 2. Resolution on the appropriation of the balance sheet profit**

The General Partner and the Supervisory Board propose that the balance sheet profit for the 2025 financial year, amounting to EUR 35,699,069.69 shall be appropriated as follows:

Distribution of a dividend of EUR 0.04 per preference share on 19,785,726 non-voting preference shares for the financial year 2025		EUR 791,429.04
Distribution in total		EUR 791,429.04
Profit carried forward to new account		EUR 34,907,640.65
Retained earnings		EUR 35,699,069.69

Pursuant to Section 58 para. 4 sentence 2 AktG in conjunction with Section 278 para. 3 AktG, entitlement to the dividend is due on the third business day following the resolution of the Annual General Meeting, i.e. on 24 July 2026. The dividend will be paid on 24 July 2026.

3. **Resolution on the discharge of the members of the Management Board of Biotest AG for the financial year 2025**

Throughout the entire 2025 financial year, the Company continued to exist in its legal form as a stock corporation (AG), operating under the firm name Biotest AG. Management was therefore exercised throughout the entire 2025 financial year by the Management Board of Biotest AG. Consequently, the subject of this agenda item is the discharge of the members of the Management Board of Biotest AG who served in the 2025 financial year.

The General Partner and the Supervisory Board propose that discharge be granted to the members of the Management Board of the Company, which operated under the firm name Biotest AG and existed in the legal form of a stock corporation (AG) in the 2025 financial year.

4. **Resolution on the discharge of the members of the Supervisory Board for the financial year 2025**

The General Partner and the Supervisory Board propose that discharge be granted for the 2025 financial year to the members of the Supervisory Board who served during the 2025 financial year.

5. **Election of the auditor and the group auditor for the financial year 2026**

The Supervisory Board, on the recommendation of its audit committee, proposes that

Deloitte GmbH
Wirtschaftsprüfungsgesellschaft
Munich, Germany

be elected as the statutory auditor and group auditor for the financial year 2026.

The audit committee has declared that its recommendation is free from undue influence by third parties in accordance with Article 16 para. 2, subparagraph 3 of Regulation (EU) No. 537/2014 and that no selection limiting clause within the meaning of Article 16 para. 6 of Regulation (EU) No. 537/2014 has been imposed on it.

II. Information and notes for the Limited Shareholders

Pursuant to Section 278 para. 3 in conjunction with Section 121 para. 3 sentences 1 and 2 in conjunction with Section 3 para. 2 AktG, non-listed partnerships limited by shares are only required, when convening the Annual General Meeting, to state the company name, the registered office of the company, the time and place of the Annual General Meeting, the agenda and the addresses set out below. The following information is therefore provided on a voluntary basis to facilitate our limited shareholders' participation in the Annual General Meeting.

Participation in the Annual General Meeting and Exercise of Voting Rights

In accordance with Section 18 of the Articles of Association, limited shareholders who have registered with the Company in due time and are listed in the Company's share register are entitled to attend the Annual General Meeting and to exercise their voting rights, to the extent that such rights exist.

Registration for the Annual General Meeting must be received by Biotest GmbH & Co. KGaA no later than the expiry of 14 July 2026 (24:00 hours CEST), at the following address:

Biotest GmbH & Co. KGaA
c/o Computershare Operations Center
80249 Munich
Email: anmeldestelle@computershare.de

The registration must be in German or English. To ensure that the registration is received in time and is not delayed by post, sending it by email is recommended.

A form for registration for the Annual General Meeting (registration form) will be sent together with the invitation letter. It is also available at www.biotest.com on the "Investor Relations/Annual General Meeting 2026" page.

Pursuant to Section 278 para. 3 in conjunction with Section 67 para. 2 sentence 1 AktG, only a limited shareholder who is registered in the share register may exercise shareholder rights in relation to the Company. Accordingly, the voting rights and other shareholder rights to which a duly registered limited shareholder is entitled at the Annual General Meeting are determined by the status of the share register on the day of the Annual General Meeting. For operational reasons, however, no changes will be made in the share register during the period from the expiry of the registration deadline on 14 July 2026, 24:00 hours (CEST), as the technically decisive record date (the so-called "Technical Record Date") until the conclusion of the Annual General Meeting (so-called "Transfer Ban"). Consequently, the status of the share register on the day of the Annual General Meeting corresponds to the status following the last change on 14 July 2026, 24:00 hours (CEST). The Transfer Ban does not constitute a restriction on the disposal of the shares. However, purchasers of shares whose change requests are received by the Company after 14 July 2026, 24:00 hours (CEST), will not be able to exercise voting rights or other shareholder rights attached to these shares, unless they obtain a proxy or authorisation to exercise such rights. In such cases, voting rights and other shareholder rights remain with the limited shareholder entered in the share register until the change is completed. All purchasers of shares in the Company who are not yet entered in the share register are therefore requested to submit transfer applications in good time. Registration for the Annual General Meeting does not block the shares; limited shareholders may freely dispose of the shares even after registration has taken place.

Upon receipt of the registration by the Company, admission tickets for the Annual General Meeting will be sent to the limited shareholders entitled to attend or their proxies. The admission tickets sent or deposited at the venue are merely organisational aids and do not constitute a prerequisite for attending the Annual General Meeting or exercising voting rights.

Only ordinary limited shareholders are entitled to exercise voting rights. Preference limited shareholders are not entitled to voting rights pursuant to Section 20.2 of the Articles of Association.

Procedure for Voting and Participation via a Proxy

Limited shareholders who meet the aforementioned requirements for participation but do not wish to attend the Annual General Meeting in person and/or exercise their voting rights in person may have their rights, in particular their voting rights, exercised by a proxy, e.g. a financial institution, a shareholders' association or another third party. In addition, we offer our ordinary limited shareholders proxy voting services through proxy representatives designated by the Company who are bound by instructions. Also in the case of representation of a limited shareholder, the requirements outlined above for participation in the Annual General Meeting and the exercise of voting rights must be observed.

If neither a financial institution nor a shareholders' association nor a person or institution treated as equivalent to these under Section 278 para. 3 in conjunction with Section 135 para. 8 AktG is authorised to exercise voting rights, the proxy must be granted in writing in accordance with Section 278 para. 3 in conjunction with Section 134 para. 3 sentence 3 AktG (Section 126b of the German Civil Code (BGB)). The revocation of a proxy and the provision of proof of authorisation to the Company must also be in writing (Section 126b BGB – *in Textform*) in accordance with Section 278 para. 3 in conjunction with Section 134 para. 3 sentence 3 AktG.

If a limited shareholder authorises more than one person, the Company may reject one or more of them. This does not affect the possibility of appointing a separate representative for the Annual General Meeting for each of the Company's shares held by a limited shareholder in different securities accounts.

Forms that can be used to grant a proxy for attendance and voting rights (ordinary limited shareholders only) or a proxy for attendance (preference limited shareholders only) will be provided to ordinary limited shareholders and preference limited shareholders respectively together with their admission ticket and are available for download on the Company's website at www.biotest.com via the "Investor Relations/Annual General Meeting 2026" page.

Proof of authorisation must either be presented by the proxy on the day of the Annual General Meeting or sent to the Company in advance of the Annual General Meeting to the following address:

Biotest GmbH & Co. KGaA
c/o Computershare Operations Center
80249 Munich
Email: anmeldestelle@computershare.de

On the day of the Annual General Meeting itself, proof of authorisation may only be submitted at the entrance and exit control point for the Annual General Meeting at the business premises of Biotest GmbH & Co. KGaA, Daimlerstraße 1 K, 63303 Dreieich, from 9:30 a.m. (CEST) until shortly before the start of voting.

Ordinary limited shareholders who wish to authorise an intermediary, a proxy advisor, a shareholders' association or one of the institutions or persons referred to in Section 278 para. 3 in conjunction with Section 135 para. 8 AktG to exercise their voting rights, please note that in such cases the institution or person to be authorised may require a specific form of proxy, as it must record the proxy in a verifiable manner in accordance with Section 278 para. 3 in conjunction with Section 135 AktG; the granting of proxy must be complete and may only contain the declarations relating to the exercise of voting rights. We therefore ask ordinary limited shareholders to consult with the person to be authorised regarding the form of the proxy in such cases. Please note the special procedure under Section 278 para. 3 in conjunction with Section 135 para. 1 sentence 5 AktG.

Ordinary limited shareholders who wish to authorise the proxy representatives designated by the Company in advance of the Annual General Meeting are requested, for organisational purposes, to

complete in full the form for granting proxy and instructions to the proxy representatives printed on the admission ticket and to send it to the address of

Biotest GmbH & Co. KGaA
c/o Computershare Operations Center
80249 Munich
Email: anmeldestelle@computershare.de

by Monday, 20 July 2026, 24:00 hours (CEST).

The proxy representatives designated by the Company are obliged to vote in accordance with the provided instructions. They may not exercise voting rights at their own discretion. In the absence of instructions, the proxy representatives will abstain from voting or will not participate in the vote.

Transmission of Information via Intermediaries via SWIFT

Registration for the Annual General Meeting (as described above under Section II) as well as the granting of proxies and, where applicable, instructions to the proxy representatives designated by the Company and, where applicable, any amendments or revocations thereof may, in accordance with Section 67c AktG, in principle also be transmitted by intermediaries either to one of the contact details set out in the relevant section above or, in accordance with SRD II in conjunction with the Implementing Regulation (EU) 2018/1212, via the following SWIFT address to the Company (receipt by the Company being decisive). Authorised SWIFT participants should use

BIC: CMDHDEMXXX; instructions via SWIFT are only possible in accordance with ISO 20022; authorisation via the SWIFT Relationship Management Application (RMA) is required.

Notifications of attendance at the Annual General Meeting must be received by the Company via SWIFT no later than the end of the final registration date, i.e. on 14 July 2026, 24:00 hours (CEST) (SWIFT Enrolment Market Deadline).

The granting of proxies and, where applicable, instructions to the proxy representatives designated by the Company, as well as any amendments, must be received by the Company no later than on 20 July 2026, 24:00 hours (CEST) (SWIFT Vote Market Deadline).

Information on the rights of limited shareholders pursuant to Section 122 para. 2, Section 126 para. 1, Section 127 and Section 131 para. 1 AktG in conjunction with Section 278 para. 3 AktG

Requests for additions to the agenda (Section 122 para. 2 in conjunction with Section 278 para. 3 AktG)

Limited shareholders whose shares together amount to one-twentieth of the share capital (i.e. EUR 1,978,572.60) or the proportionate amount of EUR 500,000.00 (corresponding to 500,000 shares) may request that items be placed on the agenda and published. Each new item must be accompanied by a reasoning or a draft resolution. The request must be submitted in wet ink (*schriftlich*) to the General Partner. The applicants must prove that they have held the shares for at least 90 days prior to the date of receipt of the request and that they will hold the shares until the General Partner has decided on the request.

Requests for additions to the agenda must be received by the Company at least 24 days before the meeting, i.e. by 26 June 2026, 24:00 hours (CEST), at the following address:

Biotest GmbH & Co. KGaA
Management of the General Partner
Biotest Management GmbH
For the attention of Prof. Dr Jörg Schüttrumpf
Landsteinerstraße 5
63303 Dreieich

Counter-motions and election proposals (Sections 126 para. 1 and 127 AktG in conjunction with Section 278 para. 3 AktG)

In addition, limited shareholders of the Company may submit counter-motions against proposals made by the General Partner and/or the Supervisory Board regarding specific items on the agenda, as well as election proposals for the election of a member of the Supervisory Board or the auditor. Counter-motions must be accompanied by a reasoning. Counter-motions and election proposals from limited shareholders must be sent exclusively to the address below. Counter-motions and election proposals sent to any other address will not be considered.

Biotest GmbH & Co. KGaA
Investor Relations
Landsteinerstraße 5
63303 Dreieich
Email to: HV2026@biotest.com

Counter-motions and election proposals received within the statutory period, i.e. by 6 July 2026, 24:00 hours (CEST), and which comply with the statutory requirements, will be made available on the Company's website at www.biotest.com via the "Investor Relations/Annual General Meeting 2026" page.

Any comments from the administration will also be published on the aforementioned website.

Right to information (Section 131 para. 1 AktG in conjunction with Section 278 para. 3 AktG)

Each limited shareholder shall, upon request, be provided with information by the General Partner at the Annual General Meeting regarding the affairs of the Company, provided that the information is necessary for the proper evaluation of an item on the agenda and that there is no right to refuse to provide information. The General Partner's duty to provide information also extends to the Company's legal and business relationships with an affiliated company, as well as to the position of the group and the companies included in the consolidated financial statements.

Notes on data protection

In order to prepare for and conduct its Annual General Meeting, the Company processes the personal data of its limited shareholders and any shareholder representatives. This data includes, in particular, the name, place of residence or address, any email address, the respective shareholding, the admission ticket number and the granting of any voting proxies. Depending on the circumstances, further personal data may also be processed, provided that it is necessary for the preparation and conduct of the Annual General Meeting. The Company's general privacy policy can be found at: <https://www.biotest.com/de/de/service/datenschutzerklaerung.cfm>.

Responsible person, purpose and legal basis

The Company is responsible for data processing. The purpose of data processing is, in particular, to comply with the requirements of stock corporation law and to enable limited shareholders and shareholder representatives to participate in the Annual General Meeting and to exercise their rights effectively before and during the Annual General Meeting. The legal basis for data processing is Article 6 para. 1 (c) of the GDPR in conjunction with Sections 67e para. 1 and 118 et seq. AktG.

Recipients

The Company appoints various service providers and consultants in connection with its Annual General Meeting. These parties receive from the Company only such personal data as is necessary for the execution of the respective assignment. The service providers and consultants process this data exclusively in accordance with the Company's instructions. Furthermore, personal data is made available to limited shareholders and shareholder representatives within the scope of the statutory provisions, namely via the list of participants.

Retention period

Personal data is stored for as long as required by law or for as long as the Company has a legitimate interest in storing it, for example in the event of judicial or extrajudicial disputes arising from the Annual General Meeting. Afterwards, the personal data will be deleted.

Data subjects' rights

Subject to the conditions set out in detail in Articles 12 et seq. of the GDPR, you may exercise your rights to access, rectification, restriction, objection or erasure in relation to your personal data or its processing, as well as the right to data portability. You also have the right to lodge a complaint with the data protection supervisory authorities in accordance with Article 77 of the GDPR.

Contact details

Biotest GmbH & Co. KGaA
Landsteinerstraße 5
63303 Dreieich
Telephone: +49- (0)6103 – 801 4406
Email: HV2026@biotest.com

You can contact our Data Protection Officer at:

ISiCO GmbH
Philipp Siedenburg
Email: datenschutz@biotest.com

Dreieich, June 2026

Biotest GmbH & Co. KGaA
The General Partner Biotest Management GmbH
The Management